N/A
N=61
A Clinical Evaluation of a Vaginal Bowel Control System for the Treatment of Fecal Incontinence in Women (LIFE)
Fecal Incontinence
Bottom Line
View on ClinicalTrials.gov: NCT01655498 ↗Enrolled (actual)
61
Serious AEs
1.6%
Results posted
May 2015
Primary outcome: Primary: Frequency of FI Episodes — 79; 86 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- vaginal bowel control system (LivSure) (Device)
- Age
- Adult, Older Adult · 19+ yrs
- Sex
- Female
- Sponsor
- Pelvalon, Inc.
- Primary completion
- Jan 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Frequency of FI Episodes |
79; 86 | — |
| SECONDARY Number of Incontinent Days |
2.1; 11.6 | — |
| SECONDARY Device-related Adverse Events |
18 | — |
Summary
The objective of this study is to obtain preliminary efficacy and safety data on the use of the LivSure System (now called the "Eclipse™ System") in women with fecal incontinence.
Eligibility Criteria
Inclusion Criteria
- History of FI for at least 6 months
- Baseline diary requirement for min # of FI episodes in a two-week period
- Ability to manage investigational device insertion and removal
- Successful fitting of study device
- Willing and able to give written informed consent to participate in the study
Exclusion Criteria
- Chronic rectal, anal or pelvic pain
- Any vaginal prolapse that extends beyond the plane of the hymen.
- Previous rectal or pelvic floor surgery within the last 12 months (24 months in the case of cancer)
- Congenital anorectal malformation
- Chronic watery diarrhea unmanageable by drugs or diet as primary cause of FI
- Inflammatory bowel disease
- Presence of a vaginal, anal, rectal or urethral fistula or anastomosis
- Presence of a vaginal, rectal or bladder tumor
- Presence of an open wound or tear in the vagina or anus by exam
- Presence or history of rectovaginal fistula
- Atrophic vaginal tissue as determined by symptoms or visualization
- Current vaginal or urinary infection requiring treatment
- History of recurrent urinary or vaginal infections
- Subject is currently pregnant or planning pregnancy in next 5 months
- Concurrent use of any intra-vaginal device that would interfere with LivSure (now called Eclipse) placement or wearing
- Any significant medical condition (e.g., significant psychiatric or neurological disorders, active alcohol/drug abuse, etc.) or other factor that the investigator believes would interfere with study participation and/or increase subject risk
Data sourced from ClinicalTrials.gov (NCT01655498). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.